Interstitial Lung Disease (ILD) Diagnostic Insights Offered by CTD Serology
|
|
- Britton Hensley
- 5 years ago
- Views:
Transcription
1 Interstitial Lung Disease (ILD) Diagnostic Insights Offered by CTD Serology Robert G Cooper Prof of Medicine (Muscle and Rheumatology)
2 Normal Alveolar Physiology
3 Contrast with ILD Pathologies Impairing Gas Transfer Parenchymal Inflammation (+/- PF) Parenchymal Fibrosis (+/- inflammation)
4 Background ILD is a heterogeneous spectrum, causing progressive dyspnoea with lethal outcomes from respiratory failure or its cardiac complications. Treatment outcomes variable, and dependant on ILD subgroup phenotype. Problem Differentiating between ILD subgroups can be considerably problematic.
5 The ILD Spectrum Groups Idiopathic (IIP) Granulomatous CTD-ILD Environmental or medicinal exposures Rare causes Idiopathic Pulmonary Fibrosis (IPF), or Usual Interstitial Pneumonia (UIP) Nonspecific Interstitial Pneumonia (NSIP) Cryptogenic Organising Pneumonia (COP) Sarcoidosis Hypersensitivity pneumonitis Rh Arthritis (UIP and non-uip) Systemic sclerosis Myositis spectrum Sjogren s Syndrome Mixed CTD Asbestos Silica Other dusts Nitrofurantoin Bleomycin Vasculitis Langerhans cell histiocytosis Eosinophilic pneumonia Acute Interstitial Pneumonia (AIP) Subgroups Undifferentiated CTD Subgroups Respiratory-bronchiolitisassociated interstitial lung disease (RB-ILD) Desquamative Interstitial Pneumonia (DIP) Lymphoid Interstitial Pneumonia (LIP) A Classification of the ILD Spectrum Adapted from Ryerson CJ, Collard HR. Update on the diagnosis and classification of ILD. Curr Opin Pulm Med 2013; 19:
6 ATS/ERS Classification Guidelines for ILD Subgroup diagnosis made according to occupational and clinical histories and a thorough clinical examination, in combination with routine serology and an HRCT. An idiopathic subgroup diagnosis can only be assigned if other diagnoses have been definitively excluded, but these guidelines did not dictate stringency of serology. Most chest clinics likely only test for RF, CCP and ANA, +/- ENAs Reliable, ILD-specific biomarkers are lacking, representing a major diagnostic issue. American Thoracic Society/European Respiratory Society International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002; 165(2):
7 ILD Diagnostic Issues Diagnosis easy if a CTD clinically obvious (e.g erosive RA or overt SSc), or an environmental trigger easily identified (e.g silica exposure in a stone mason). But, environmental triggers may be missing and clinical signs absent or very subtle. If history, examination and routine serology give no clue as to the actual diagnosis, this is of necessity assigned radiologically, i.e by HRCT - idiopathic UIP, idiopathic NSIP, idiopathic COP etc.
8 Peripheral reticular changes IPF UIP or Probable UIP Non-Responsive to Immunosuppression
9 CTD-ILD - Ground Glass Changes Responsive to Immunosuppression (not always) Ground glass changes
10 HRCT as Predictor of ILD Mortality IPF vs CTD-ILD Park JH et al. Prognosis of fibrotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med 2007; 175(7):
11 HRCT-Specific Problems When history is non diagnostic, CTD signs absent and serology unhelpful, HRCT use can still be problematic: - HRCT images not necessarily ILD subgroup-specific. - HRCT images may vary within ILD subgroups. - Between-assessor variability of image reporting, so MDTs of great importance.
12 Idiopathic Pulmonary Fibrosis (IPF) Fatal in ~ 50% of cases within only 3-4 years. Aggressive corticosteroid immunosuppression is ineffective, and now proven as harmful, so now contra-indicated. Pirfenidone and nintedanib do slow IPF progression, but these drugs are very expensive, so can only be used in tertiary referral ILD clinics, e.g Aintree (Merseyside - NW Coast), Wythenshawe (Gt Manchester) etc.
13 CTD ILD Generally comprise an inflammatory component (i.e ground glass changes) so usually responsive to steroids +/- DMARDS, at least in part. Once Rx initiated, PFTs usually stabilise, though not always. Role of Rituximab unclear. Role of anti-fibrotic drugs also unclear, but trials ongoing or planned in RA-ILD and SSc-ILD.
14 Diagnostic Accuracy Issues Between-subgroup treatment response differences mean that making an accurate diagnosis is crucial in every case, to ensure accurate delivery of either targeted immuno-suppression or targeted fibroinhibition. Lack of reliable, ILD-specific, diagnostic biomarkers means that potentially dangerous diagnostic lung biopsies are still necessary.
15 Therapeutic Difficulties Arising Due to The Lack of ILD- Specific Biomarkers Covert CTD-ILD or IIP? IIP or covert CTD-ILD?
16 How can rheumatology help?
17 Polymyositis Dermatomyositis 1999 Idiopathic Inflammatory Myopathies (IIM) Malignancy Myositis-CTD overlap Juvenile Dermatomyositis
18 Idiopathic Inflammatory Myopathies (IIM) Background in 1999 Myositis is an acquired inflammatory cell infiltration in skeletal muscle, causing myalgia, fatigue and weakness, and thus disability (usually chronic). Death directly due to IIM (i.e ventilatory failure) is rare. Infiltrations with variable numbers of CD8+ and CD4+ T-cells, with some B-cells and fewer macrophages. Multi-system inflammation, and potentially affecting: muscle +/- lungs +/- skin +/- joints Causative mechanisms remains poorly understood, so mechanistic research is still vital.
19 Mechanistic Issues in IIM in 1999 Disease Causation: Genes vs Environment HLA-DRB1*03 (DR3)? Viruses
20 Roles of HLA and cytotoxic T-cells in IIM Klein J & Sato A. N Eng J Med. 2000, 343:702-9 Cytotoxic T-cells cause muscle cell damage and weakness
21 Clinical Difficulties with IIM Many IIM mimics, so only too easy to misdiagnose other myo-pathologies as idiopathic inflammatory myositis. Treatment responses variable, but usually incomplete, so most patients (~75%) never regain normal strength or function. Most UK rheumatologists will only see 8-10 IIM cases in a whole career, so mechanistic research had been very difficult to undertake. So, action needed!!
22 UK Adult Onset Myositis Immunogenetic Collaboration (AOMIC) - Set up by RGC/WERO 2000
23 AOMIC - UKMYONET (RGC/WERO/HC/JL) Case Recruitment Caucasians/Non-Caucasians - Phenotype details, serum and DNA - Myositis probable/definite according to Bohan & Peter Controls (n=537) PM/DM/OL (n >1750) IBM (n >230) JDM* (n >350) *(JDRG collaboration LW/CP)
24 Aims of AOMIC - UKMYONET Immediate - To recruit ethnically homogeneous myositis subgroup cohorts of sufficient size to enable statistically meaningful between-subgroup genetic and serological comparisons. Longer-term - To elucidate disease mechanisms, so as to facilitate future therapeutic developments.
25 % Dermatomyositis Correlation of DM/(DM + PM) with UV exposure Pathogenic role for UV? N = 919, weighted r = 0.94, P < 4 X UV Exposure (Joules/ m 2 ) Guatemala Mexico city Guadalajara New Delhi Santiago Tokyo Seoul Bethesda Barcelona Warsaw Aachen Nijmgen Stockholm Glasgow (Diagram courtesy of Prof Fred Miller, NIH, USA))
26 Interaction between smoking and HLA-DRB1 (SE) in two different subsets of RA Relative risks for eversmokers and neversmokers classified on presence of Shared epitop ACPA-negative compared to neversmokers RA with no shared epitope genes (all cases are anti-citruline an ACPA-positive Relative risks for eversmokers RA and neversmokers classified on presence of Shared epitope genes negative) compared to neversmokers with no shared epitope genes (all cases are anti-citruline anti body positive) 25 40, OR Relative Risk Ever Smokers 0 Ever Smokers No SE Single SE Double SE Never Smokers No SE Single SE Double SE Never Smokers Never Smokers Ever Smokers Never Smokers Ever Smokers Klareskog et al Arthritis Rheum 2006;54:38-46
27 log odds ratio & 95% confidence interval Anti-Jo-1 status by smoking and HLA-DRB1* Index Smoke - Smoke + Smoke - Smoke + DRB1*03 - DRB1*03 - DRB1*03 + DRB1*03 + Chinoy H. et al, Ann Rheum Dis 2012 Jun;71(6):961-5
28 Mechanistic Clues Environmental triggers: E.g infections (viral), UV (light sensitivity in DM), malignancy association (CAM), smoking (Jo-1 and DR3 associated), drugs (statins) etc Genetic and serological factors (associated):
29 Serological Results A large spectrum of myositis autoantibodies, correlating with a large spectrum of IIM subgroups.
30 Myositis-Specific and -Associated Autoantibodies (MSA and MAA) SRP HMGCoAR (DR11) SEVERE MYOPATHY NECROTISING MYOPATHY Jo-1 (DR3) SAE SKIN DISEASE++ Mi-2 (DR7) PmScl (DR3) Ku RNP CTD-IIM (MAA) EIF3 MILD DM Ha EJ PL-7 Anti-synthetase KS LUNG DISEASE autoantibodies LUNG DISEASE++ SINE MYOSITIS OJ PL-12 Zo MDA5 (DR15) CALCINOSIS NXP2 MALIGNANCY TIF1-gamma (DQB1*02) Ro La IBM 5NT1A (DR13)
31 IIM - A Remarkable Disease Spectrum Myositis specific autoantibodies Clinical phenotypes in adults and children Anti-Synthetase (DR3) Anti-SRP Anti-Mi-2 (DR7) Anti-TIF1g etc
32 ANTI-SYNTHETASE SYNDROME (ASS) Anti-synthetase autoantibodies Overall frequency 30% adult IIM patients Myositis (PM or DM) Ha Jo-1 Raynaud s Arthritis (patients often initially misdiagnosed as RA) Zo EJ Anti-synthetase autoantibodies Mechanic s hands Gottron s lesions (DM only) OJ Fever PL-7 KS PL Yoshifuji H. Autoimmunity 2006;39: Gunawardena H. Rheumatology 2009;48: Review. Interstitial Lung Disease (ILD)
33 DM - Heliotrope with Periorbital Oedema
34 DM - Gottron s papules Erythematous to violaceous papules and plaques over the extensor surfaces of MCP and IP joints & other large joints in a symmetric distribution.
35 Mechanics Hands in a Jo-1+ve Myositis Patient with ASS
36 Raynaud s Phenomenon
37 Thermography - Cold Challenge Test
38 Nail-Fold Capillary Abnormalities (As seen by use of ophthalmoscope) (+ 20 D Lens) Magnifying Glass
39 Scleroderma - IIM - ILD Overlap
40 Scoring Scleroderma Skin
41 MSA/MAA are also SURROGATE biomarkers of ILD SRP SEVERE MYOPATHY SAE Mi-2 HMGCR NECROTISING MYOPATHY Jo-1 SKIN DISEASE++ PmScl Ku U1RNP CTD-IIM (MAA) EIF3 Ha EJ PL-7 LUNG DISEASE - ILD Anti-synthetase autoantibodies LUNG DISEASE++ SINE MYOSITIS KS PL-12 OJ Zo MDA5 CALCINOSIS NXP2 MALIGNANCY TIF1-gamma Ro La IBM 5NT1A MILD DM
42 ILD-Specific and ILD-Associated Autoantibodies (ISA and IAA) Clinically Amyopathic CTD-ILD: If ILD is the only clinical feature of a CTD, then an MSA would also represent an ISA Jo-1 Other SSc-specific Abs also associated with ILD PmScl Ku U1RNP CTD-ILD (IAA) EJ Ha LUNG DISEASE - ILD Anti-synthetase autoantibodies CTD-ILD (ISA) Ro La PL-7 KS LUNG DISEASE++ SINE MYOSITIS OJ PL-12 Zo MDA5 Fulminant ILD Especially in Oriental Asians
43 Anti-MDA 5 A myositis specific antibody, usually associates with clinically amyopathic DM (CADM). Also associates with a very fulminant ILD (often lethal within only weeks or months, especially so in Oriental Asians). Little or no response to steroids, cyclophosphamide, MMF, IVIG or Rituximab. Disease mechanisms unknown.
44 Eurimmun Line-Blot Technology Currently Available IIM and SSc Specificities
45 A Growing Clinical Spectrum of ILDs Multiple ISA/IAA autoantibodies Multiple ILD clinical phenotypes Anti-Jo-1 vs PL7 Anti-U1RNP Anti-PMScl Anti-MDA5 etc
46 UK-BILD Aiming to Improve Diagnostic Performance and Provide Mechanistic Insights in ILD Robert G Cooper (Study PI) Prof Medicine & Hon Consultant Rheumatologist
47 UK-BILD: The UK Biomarkers in Interstitial Lung Disease study. A UK-wide cross-sectional recruitment of ILD cases comprehensive across the ILD spectrum. Has recruited ~ 2850 cases to date.
48 UK-BILD National recruitment from 38 centres. Case recruitment comprehensive across the ILD spectrum. Patients must have HRCT-proven ILD, and their investigations must have included routine serology. Samples harvested: Completed 2 page clinical pro forma and whole blood for DNA genotyping (UoM) and EDTA plasma for serotyping by immuno-precipitation (UoB).
49 UK-BILD: Case Accrual by ILD Subgroup to Nov
50 The ILD Spectrum Groups Idiopathic (IIP) Granulomatous CTD-ILD Environmental or medication exposures Rare causes Idiopathic Pulmonary Fibrosis (IPF), or Usual Interstitial Pneumonia (UIP) Nonspecific Interstitial Pneumonia (NSIP) Cryptogenic Organising Pneumonia (COP)? CTD? CTD Acute Interstitial Pneumonia (AIP) Sarcoidosis Hypersensitivity pneumonitis Subgroups Rh Arthritis Systemic sclerosis Myositis spectrum Sjogren s Syndrome Mixed CTD Undifferentiated CTD Asbestos Nitrofurantoin Bleomycin Silica Other dusts Vasculitis Langerhans cell histiocytosis Eosinophilic pneumonia Subgroups Respiratory-bronchiolitisassociated interstitial lung disease (RB-ILD) Desquamative Interstitial Pneumonia (DIP) Lymphoid Interstitial Pneumonia (LIP) Some IIP cases may be reclassified CTD-ILD subgroups Adapted from Ryerson CJ, Collard HR. Update on the diagnosis and classification of ILD. Curr Opin Pulm Med 2013; 19:
51 Other Members of UK-BILD Team Dr Lisa Spencer (Co-I, Chest Physician, Aintree University Hospital, Liverpool, eamil: Mr Paul New (Research Associate, University of Liverpool, Dr Janine Lamb (Co-I, Non-Clinical Scientist heading up the Centre for Integrated Genomic Medical Research (CIGMR), University of Manchester, Prof Neil McHugh (Co-I, Director of Immunoprecipitation National Reference Laboratory, University of Bath, Dr Zoe Betteridge (Non-Clinical Scientist running Immuno-precipitation Laboratory, University of Bath, 38 UK ILD case recruitment sites to date.
52 UoL
53 Institute of Ageing and Chronic Disease Thank you for listening
54 Acknowledgements UoLiverpool Adam Lightfoot Robert Cooper Patients/UoManchester Janine Lamb Simon Rothwell Robert Cooper Hector Chinoy William Ollier Joanna Parkes James Lilleker Alex Oldroyd John Bowes Hazel Platt UoBath/UKMYONET Neil McHugh Zoe Betteridge Patrick Gordon David Isenberg Mike Hanna Pedro Machado Harsha Gunawardena James Miller Paul New EuMyonet/Euromyositis Lucy Wedderburn Gouchun Wang Louise Diedrichson Jens Schmidt Jiri Vencovsky Paula Oakley Olivier Benveniste Ingrid Lundberg MYOGEN/MYONET Ingrid E. Lundberg Frederick W. Miller Peter K. Gregersen Jiri Vencovsky Katalin Danko Lucy R. Wedderburn Vidya Limaye Albert Selva-O'Callaghan Michael G. Hanna Pedro Machado Lauren M. Pachman Ann M. Reed Lisa G. Rider Øyvind Molberg Olivier Benveniste Pernille Mathiesen Timothy Radstake Andrea Doria Jan De Bleecker Boel De Paepe Britta Maurer Leonid Padyukov Terrance P. O'Hanlon Annette Lee
Autoantibodies in the Idiopathic Inflammatory Myopathies
Autoantibodies in the Idiopathic Inflammatory Myopathies Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic Rochester, MN The Myositis Association Annual Conference St. Louis, MO Sept. 25,
More informationAutoantibodies andprognosis. Jiří Vencovský Institute of Rheumatology, Prague, Czech Republic
Autoantibodies andprognosis Jiří Vencovský Institute of Rheumatology, Prague, Czech Republic HeterogeneityofIIMs Diagnosis Polymyositis Dermatomyositis IBM Necrotising myopathy Paraneoplastic Amyopathic
More informationAutoantibodies in Idiopathic Inflammatory Myopathies. Vidya Limaye Rheumatology Department Royal Adelaide Hospital
Autoantibodies in Idiopathic Inflammatory Myopathies Vidya Limaye Rheumatology Department Royal Adelaide Hospital Idiopathic Inflammatory Myopathies (IIM) Heterogeneous group of systemic autoimmune syndromes
More informationCTD-related Lung Disease
13 th Cambridge Chest Meeting King s College, Cambridge April 2015 Imaging of CTD-related Lung Disease Dr Sujal R Desai King s College Hospital, London Disclosure Statement No Disclosures / Conflicts of
More informationWhat are Autoantibodies and how do they work in Myositis?
What are Autoantibodies and how do they work in Myositis? Neil McHugh, University of Bath and Royal National Hospital for Rheumatic Diseases Orlando September 2015 Royal National Hospital for Rheumatic
More informationMyositis and Your Lungs
Myositis and Your Lungs 2013 TMA Annual Patient Meeting Louisville, Kentucky Chester V. Oddis, MD University of Pittsburgh Director, Myositis Center Myositis Heterogeneous group of autoimmune syndromes
More informationDisclosures. Clinical Approach: Evaluating CTD-ILD for the pulmonologist. ILD in CTD. connective tissue disease or collagen vascular disease
Disclosures Clinical Approach: Evaluating CTD-ILD for the pulmonologist Industry relationships: Actelion, atyr Pharma, Boehringer-Ingelheim, Genentech- Roche, Gilead Aryeh Fischer, MD Associate Professor
More informationSignificance of antibody testing in idiopathic inflammatory myopathies
2/0/20 Significance of antibody testing in idiopathic inflammatory myopathies Jiří Vencovský Institute of Rheumatology, Prague Diagnosis Polymyositis Juvenile DM (JPM) Paraneoplastic Myositis in overlap
More informationWhat your autoantibodies tell us about your disease. Mark Gourley, MD
What your autoantibodies tell us about your disease Mark Gourley, MD The Importance of the Immune System Defends us against foreign invaders Self (cancer) and Nonself (virus, bacteria, etc.) But, if the
More informationDiagnosing ILD. What is important in 2016? Chris Grainge
Diagnosing ILD What is important in 2016? Chris Grainge Senior Staff Specialist Respiratory Medicine John Hunter Hospital Conjoint A/Prof University of Newcastle Conflict of interest I have acted as a
More informationOverview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy
Overview of Idiopathic Pulmonary Fibrosis: Diagnosis and Therapy Jeff Swigris, DO, MS Director, ILD Program National Jewish Health Disclosures Speaker - Boehringer Ingelheim and Genentech Objectives Describe
More informationClinical Laboratory. 14:42:00 SSA-52 (Ro52) (ENA) Antibody, IgG 1 AU/mL [0-40] Oct-18
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Rheumatoid Factor
More informationThis month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma tests/panels.
February 20, 2017 Client Letter Test Update February 2017 Dear Colleague: This month, we are very pleased to introduce some new tests for Scleroderma as well as some test changes to our existing scleroderma
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationNon-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
More informationDiagnosis of Connective Tissue Disease Interstitial Lung Disease in 2016
Diagnosis of Connective Tissue Disease Interstitial Lung Disease in 2016 A/Prof Tamera Corte TSANZ Annual Conference: Perth 2016 Royal Prince Alfred Hospital, Sydney, Australia Sydney Medical School, University
More informationEnvironmental Influence in Autoimmune Diseases. Mark Gourley, MD
Environmental Influence in Autoimmune Diseases Mark Gourley, MD Newsweek January, 2003 Current Knowledge of Environment and Myositis Environment Genes Autoimmunity What Is an Environmental Exposure?
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationRecent advances in myositis
Recent advances in myositis Dr Hector Chinoy PhD FRCP @drhectorchinoy Senior Lecturer / Honorary Consultant Rheumatologist Salford Royal NHS Foundation Trust Manchester Academic Health Science Centre The
More informationOverview of Diagnostic Autoantibodies in Inflammatory Myopathy
Overview of Diagnostic Autoantibodies in Inflammatory Myopathy Minoru Satoh, M.D., Ph.D. Research Associate Professor of Medicine Division of Rheumatology and Clinical Immunology University of Florida
More informationDIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY?
NIHR Southampton Respiratory Biomedical Research Unit DIFFERENCES IN FIBROPROLIFERATIVE HEALING IN EXOGENEOUS AND IDIOPATHIC ILDs. ARE THERE ANY? Fibrosing Interstitial Lung Diseases CPFS/WASOG/AIPO/ERS
More informationIdiopathic inflammatory myopathies
Myositis and cancer Idiopathic inflammatory myopathies Primary idiopathic polymyositis Primary idiopathic dermatomyositis Juvenile poly/dermatomyositis Myositis associated with another CTD Myositis associated
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationAnnual Rheumatology & Therapeutics Review for Organizations & Societies
Annual Rheumatology & Therapeutics Review for Organizations & Societies A Rheumatologist s Approach to Interstitial Lung Disease Outline ILD classification and patterns in CTD The clinical landscape and
More informationMyositis 101. Steven R. Ytterberg, M.D. Division of Rheumatology Mayo Clinic, Rochester, MN
Myositis 101 Steven R. Ytterberg, M.D. Rheumatology Mayo Clinic, Rochester, MN Myositis Association Annual Conference Louisville, KY Sept. 6 & 7, 2018 Disclosures Consulting: Dynavax Pfizer Off-label use:
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More informationClinical Laboratory. [None
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Double-Stranded DNA (dsdna) Ab IgG ELISA Detected * [None 18-289-900151 Detected] Double-Stranded DNA (dsdna) Ab IgG
More informationIDIOPATHIC INFLAMMATORY MYOPATHIES AND RELATED DISORDERS. Franclo Henning Division of Neurology Tygerberg Hospital
IDIOPATHIC INFLAMMATORY MYOPATHIES AND RELATED DISORDERS Franclo Henning Division of Neurology Tygerberg Hospital Classification systems Clinical (Bohan and Peter) Clinico-pathological (Dalakas & others)
More informationHUNGARIAN MYOSITIS COHORT
CLINICAL ADVANCES OF ANTI- TIF1Γ AUTOANTIBODY IN A HUNGARIAN MYOSITIS COHORT Melinda Nagy-Vincze 1, Zoltán Griger 1, Levente Bodoki 1, Zsuzsa Szankai 1, Zoe E. Betteridge 2, Katalin Dankó 1 1 University
More informationLiebow and Carrington's original classification of IIP
Liebow and Carrington's original classification of IIP-- 1969 Eric J. Stern MD University of Washington UIP Usual interstitial pneumonia DIP Desquamative interstitial pneumonia BIP Bronchiolitis obliterans
More informationA Review of Interstitial Lung Diseases. Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco
A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Why it is important Definition/Classification
More informationEpidemiology and classification of smoking related interstitial lung diseases
Epidemiology and classification of smoking related interstitial lung diseases Šterclová M. Department of Respiratory Diseases, Thomayer Hospital, Prague, Czech Republic Supported by an IGA Grant No G 1207
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More informationIPF: Epidemiologia e stato dell arte
IPF: Epidemiologia e stato dell arte Clinical Classification Diffuse parenchimal lung diseases Exposure-related: - occupational - environmental - medication Desquamative interstitial pneumonia Idiopathic
More informationFinancial disclosure COMMON DIAGNOSES IN HRCT. High Res Chest HRCT. HRCT Pre test. I have no financial relationships to disclose. Anatomy Nomenclature
Financial disclosure I have no financial relationships to disclose. Douglas Johnson D.O. Cardiothoracic Imaging Gaston Radiology COMMON DIAGNOSES IN HRCT High Res Chest Anatomy Nomenclature HRCT Sampling
More informationA Review of Interstitial Lung Diseases
Outline A Review of Interstitial Lung Diseases Paul J. Wolters, MD Associate Professor Department of Medicine University of California San Francisco Overview of diagnosis in ILD Why it is important Definition/Classification
More informationInflammatory Myopathies 4 th year MBBS. Marwan Adwan MBChB, MSc, MRCPI, MRCP(rheum) Consultant Rheumatologist
Inflammatory Myopathies 4 th year MBBS Marwan Adwan MBChB, MSc, MRCPI, MRCP(rheum) Consultant Rheumatologist Case A 64 woman presents with erythematous itchy rash over back of hands & forehead. For 1 month
More informationThe many faces of myositis. Marianne de Visser Academic Medical Centre Dept of Neurology Amsterdam The Netherlands
The many faces of myositis Marianne de Visser Academic Medical Centre Dept of Neurology Amsterdam The Netherlands Outline of the presentation Classification Diagnosis Therapy Prognosis Diagnostic criteria
More informationDisclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None
Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona
More informationEXTENDED REPORT. Clinical and epidemiological research
Additional supplementary tables is published online only. To view the fi les please visit the journal online (http://ard.bmj.com/ content/71/6.toc). 1 Rheumatic Diseases Centre, Manchester Academic Health
More informationDermatomyositis Advice from Experts: Improving Your Medical Dermatology Diagnostic and Management Skills Jeffrey P. Callen, MD Professor of Medicine
Dermatomyositis Advice from Experts: Improving Your Medical Dermatology Diagnostic and Management Skills Jeffrey P. Callen, MD Professor of Medicine (Dermatology) University of Louisville Learning Objectives
More informationIdiopathic inflammatory muscle diseases. Dr. Paul Etau Ekwom MBChB, MMED Kenyatta National Hospital, Nairobi-Kenya
Idiopathic inflammatory muscle diseases. Dr. Paul Etau Ekwom MBChB, MMED Kenyatta National Hospital, Nairobi-Kenya I.W, 28 YRS, FEMALE SHOP STEWARD Referred to KNH on 16/06/09 from Thika Nursing Home Weakness
More information*Pari Basharat ABSTRACT OVERVIEW OF IDIOPATHIC INFLAMMATORY MYOPATHIES
IDIOPATHIC INFLAMMATORY MYOPATHIES: ASSOCIATION WITH OVERLAP MYOSITIS AND SYNDROMES: CLASSIFICATION, CLINICAL CHARACTERISTICS, AND ASSOCIATED AUTOANTIBODIES *Pari Basharat University of Western Ontario,
More informationUpdate on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationIPF - Inquadramento clinico
IPF - Inquadramento clinico Sergio Harari Unità Operativa di Pneumologia UTIR Servizio di Fisiopat. Resp. e Emodinamica Polmonare Ospedale S. Giuseppe, Milano Clinical Classification Diffuse parenchimal
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationManish Powari Regional Training Day 10/12/2014
Manish Powari Regional Training Day 10/12/2014 Large number of different types of Interstitial Lung Disease (ILD). Most are very rare Most patients present with one of a smaller number of commoner diseases
More informationMyositis and Autoimmune ILD
Myositis and Autoimmune ILD 2018 AURA Annual Meeting Sedona, Arizona June 2, 2018 Chester V. Oddis, MD Director, Myositis Center University of Pittsburgh Disclosures Genentech: Clinical trial support Idera:
More informationClinical Laboratory. 14:41:00 Complement Component 3 50 mg/dl Oct-18
Clinical Laboratory Procedure Result Units Ref Interval Accession Collected Received Thyroid Peroxidase (TPO) Antibody 5.0 IU/mL [0.0-9.0] 18-289-900139 16-Oct-18 Complement Component 3 50 mg/dl 18-289-900139
More informationE vidence for a significant myositis cancer association has
1345 EXTENDED REPORT The diagnostic utility of myositis autoantibody testing for predicting the risk of cancer-associated myositis Hector Chinoy, Noreen Fertig, Chester V Oddis, William E R Ollier, Robert
More informationIdiopathic inflammatory myopathies excluding inclusion body myositis
Idiopathic inflammatory myopathies excluding inclusion body myositis Marianne de Visser, Dept. of Neurology, Academic Medical Centre, Amsterdam, The Netherlands The idiopathic inflammatory myopathies (IIMs),
More informationDiagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines
Diagnosing Idiopathic Pulmonary Fibrosis on Evidence-Based Guidelines Rebecca Keith, MD Assistant Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO Objectives
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationCLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD)
CLEARING THE AIR ON DIFFUSE PARENCHYMAL (INTERSTITIAL) LUNG DISEASE (ILD) David Northrop MBA, RRT Assistant Director of Respiratory Therapy Services The University of Kansas Health System Clinical Assistant
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationIdiopathic inflammatory myopathies and the lung
EUROPEAN RESPIRATORY UPDATE IDIOPATHIC INFLAMMATORY MYOPATHIES Idiopathic inflammatory myopathies and the lung Jean-Christophe Lega 1,2, Quitterie Reynaud 1, Alexandre Belot 3, Nicole Fabien 4, Isabelle
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationTools to Aid in the Accurate Diagnosis of. Connective Tissue Disease
Connective Tissue Disease Tools to Aid in the Accurate Diagnosis of Connective Tissue Disease Connective Tissue Disease High quality assays and novel tests Inova offers a complete array of assay methods,
More informationInternational consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
More informationCOI: no conflicts of interest to declare
Idiopathic versus secondary Usual Interstitial Pneumonia (UIP) pattern in a series of 96 consecutive surgical lung biopsies: The value of histologic ancillary findings in a multidisciplinary discussion
More informationThe Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page
The Egyptian Journal of Hospital Medicine (July 2017) Vol.68 (2), Page 1135-1140 Role of High Resolution Computed Tomography in Diagnosis of Interstitial Lung Diseases in Patients with Collagen Diseases
More informationINCREASING INCIDENCE OF IMMUNE MEDIATED NECROTIZING MYOPATHY SINGLE CENTRE EXPERIENCE
INCREASING INCIDENCE OF IMMUNE MEDIATED NECROTIZING MYOPATHY SINGLE CENTRE EXPERIENCE Martin Klein 1,2*, Heřman Mann 1,2*, Lenka Pleštilová 1,2, Josef Zámečník 3, Zoe Betteridge 4, Neil McHugh 4, Jiří
More informationINTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program
More informationCurrent diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM
Medicine, Nursing and Health Sciences Current diagnostic recommendations for ILD: The multidisciplinary meeting Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University
More informationDiscovery, Understanding, and Progress in Myositis
Discovery, Understanding, and Progress in Myositis Steven Ytterberg, M.D. TMA Annual Patient Conference New Orleans, LA Sept. 2, 2016 Disclosures Financial: Dynavax Corp. Pfizer Mallinckrodt American Board
More informationAutoantibodies to a 140-kd Polypeptide, CADM-140, in Japanese Patients With Clinically Amyopathic Dermatomyositis
ARTHRITIS & RHEUMATISM Vol. 52, No. 5, May 2005, pp 1571 1576 DOI 10.1002/art.21023 2005, American College of Rheumatology Autoantibodies to a 140-kd Polypeptide, CADM-140, in Japanese Patients With Clinically
More information2 nd Global Conference on Myositis May 5-8, 2017 Bolger Center, Potomac, MD, USA All Times Listed are US Eastern Standard Time
2 nd Global Conference on Myositis May 5-8, 2017 Bolger Center, Potomac, MD, USA All Times Listed are US Eastern Standard Time Friday May 5 7:00-8:00 am Pre-Conference Registration Pathology Pre-Conference
More informationMultidisciplinary Diagnosis in Action: Challenging Case Presentations
Multidisciplinary Diagnosis in Action: Challenging Case Presentations Interstitial Lung Disease: Advances in Diagnosis and Management UCSF CME November 8, 2014 Case 1 69 yo M 3 year history of intermittent
More informationIdiopathic Pulmonary Fibrosis Treatable and Not Idiopathic
Idiopathic Pulmonary Fibrosis Treatable and Not Idiopathic Brett Ley, MD University of California San Francisco CTS 1/26/18 Disclosures Speaker s bureau honorarium from Genentech (makers of pirfenidone)
More informationProgress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More informationDefinition, classification and epidemiology
Interstitial Lung Diseases Definition, classification and epidemiology Haluk Türktaş Professor of Pulmonary Medicine Gazi University Ankara Interstitial Lung Diseases Definition of ILD A diverse group
More information2 nd Global Conference on Myositis May 5-8, 2017 Bolger Center, Potomac, MD, USA All Times Listed are US Eastern Standard Time
2 nd Global Conference on Myositis May 5-8, 2017 Bolger Center, Potomac, MD, USA All Times Listed are US Eastern Standard Time Friday May 5 7:00-8:00 am Pre-Conference Registration Pathology Pre-Conference
More informationINHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD)
THE INCREASE STUDY INHALED TREPROSTINIL IN PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE (PH-ILD) Peter Smith, PharmD Senior Director Product Development, United Therapeutics Corporation 2 SAFE
More informationChallenges in the classification of fibrotic ILD
Review SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2015; 32; Suppl. 1: 4-9 Mattioli 1885 Challenges in the classification of fibrotic ILD Elisabeth Bendstrup 1, Toby M. Maher 2, Effrosyni D. Manali
More informationPL-7 and Anti-Jo-1 Antibodies. publication is available at link.sp
NAOSITE: Nagasaki University's Ac Title Author(s) Comparison of Pulmonary Involvement PL-7 and Anti-Jo-1 Antibodies Tomonaga, Masaomi; Sakamoto, Noriho Tomoyuki; Harada, Tatsuhiko; Nakash Shintaro; Horai,
More informationNovel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies
Novel Classification of Idiopathic Inflammatory Myopathies Based on Overlap Syndrome Features and Autoantibodies Analysis of 100 French Canadian Patients Yves Troyanov, MD, Ira N. Targoff, MD, Jean-Luc
More informationCASE REPORT. Introduction. Case Report
doi: 10.2169/internalmedicine.9553-17 http://internmed.jp CASE REPORT Successful Treatment of Rapidly Progressive Unclassifiable Idiopathic Interstitial Pneumonia with Anti-melanoma Differentiation-associated
More informationArticle (Accepted version) (Refereed)
Charles Sharp, Melanie McCabe, Nick Dodds, Anthony Edey, Lloyd Mayers, Huzaifa Adamali, Ann B. Millar and Harsha Gunawardena Rituximab in autoimmune connective tissue disease associated interstitial lung
More informationBudsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital
Budsakorn Darawankul, MD. Maharat Nakhon Ratchasima Hospital Outline What is ANA? How to detect ANA? Clinical application Common autoantibody in ANA diseases Outline What is ANA? How to detect ANA? Clinical
More informationConnective Tissue Disease-Associated Interstitial Lung Disease
CHEST Commentary Connective Tissue Disease-Associated Interstitial Lung Disease A Call for Clarification Aryeh Fischer, MD ; Sterling G. West, MD ; Jeffrey J. Swigris, DO ; Kevin K. Brown, MD ; and Roland
More informationBronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy
Idiopathic Pulmonary Fibrosis Bronchoalveolar Lavage and Histopathologic Diagnosis Based on Biopsy JMAJ 46(11): 469 474, 2003 Yukihiko SUGIYAMA Professor, Division of Pulmonary Medicine, Department of
More informationInterstitial Pneumonia Related to Undifferentiated Connective Tissue Disease Pathologic Pattern and Prognosis
[ Original Research Diffuse Lung Disease ] Interstitial Pneumonia Related to Undifferentiated Connective Tissue Disease Pathologic Pattern and Prognosis Ho-Cheol Kim, MD ; Wonjun Ji, MD ; Mi Young Kim,
More informationDiffuse interstitial lung diseases (DILDs) are a heterogeneous group of non-neoplastic, noninfectious
Focused Issue of This Month Diagnostic Approaches to Diffuse Interstitial Lung Diseases Dong Soon Kim, MD Department of Pulmonary and Critical Care Medicine, University of Ulsan College of Medicine E -
More informationLines and crackles. Making sense of ILD
Lines and crackles Making sense of ILD Case JM 65 year old male Gradual shortness of breath, going on over a year Some dry cough Ex-smoker, quit 10 years ago Crackles in the bases CXR presented Sent to
More informationClinical Differences Between Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis and Classic Dermatomyositis
CHEST Clinical Differences Between Interstitial Lung Disease Associated With Clinically Amyopathic Dermatomyositis and Classic Dermatomyositis Hiroshi Mukae, MD, PhD; Hiroshi Ishimoto, MD; Noriho Sakamoto,
More informationINTERSTITIAL LUNG DISEASE Dr. Zulqarnain Ashraf
Indep Rev Jul-Dec 2018;20(7-12) Dr. Zulqarnain Ashraf IR-653 Abstract: ILD is a group of diseases affect interstitium of the lung. Repeated insult to the lung cause the interstitium to be damaged. Similarly
More informationDRAFT FOR POC BOARD Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults)
Clinical Commissioning Policy Proposition: Rituximab in Connective Tissue Disease associated Interstitial Lung Disease (adults) Reference: NHS England A/14/X01 CHECK Information Reader Box (IRB) to be
More informationCase 4 History. 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar
Case 4 History 58 yo man presented with prox IP joint swelling 2 months later pain and swelling in multiple joints Chest radiograph: bi-basilar basilar infiltrates suggestive of pulmonary fibrosis Open
More informationTitle:Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease
Author's response to reviews Title:Pemetrexed for advanced non-small cell lung cancer patients with interstitial lung disease Authors: Motoyasu Kato (mtkatou@juntendo.ac.jp) Takehito Shukuya (tshukuya@juntendo.ac.jp)
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationNONE OVERVIEW FINANCIAL DISCLOSURES UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF (UIP) FOR PATHOLOGISTS. IPF = Idiopathic UIP Radiologic UIP Path UIP
UPDATE ON IDIOPATHIC PULMONARY FIBROSIS/IPF () FOR PATHOLOGISTS Thomas V. Colby, M.D. Professor of Pathology (Emeritus) Mayo Clinic Arizona FINANCIAL DISCLOSURES NONE OVERVIEW IPF Radiologic Dx Pathologic
More informationClinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies
CME Review Clinical and pathophysiological significance of myositis-specific and myositis-associated autoantibodies Autoantibodies to various cellular constituents are detected in the sera of patients
More informationInterstitial Lung Disease in the Connective Tissue Diseases
Interstitial Lung Disease in the Connective Tissue Diseases Danielle Antin-Ozerkis, MD a, *, Ami Rubinowitz, MD b, Janine Evans, MD c, Robert J. Homer, MD, PhD d, Richard A. Matthay, MD e KEYWORDS Connective
More informationUtility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting
International Journal of Clinical Rheumatology Review ositis Utility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting Autoantibodies directed against nuclear or cellular
More informationHLA DPB1 associations differ between DRB1*03 positive anti-jo-1 and anti-pm-scl antibody positive idiopathic inflammatory myopathy
Rheumatology 2009;48:1213 1217 Advance Access publication 18 August 2009 doi:10.1093/rheumatology/kep248 HLA DPB1 associations differ between DRB1*03 positive anti-jo-1 and anti-pm-scl antibody positive
More information